Marija Mitrović
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marija Mitrović has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ana Petakov
Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, 11000 Belgrade, Serbia
4 shared publications - Iva Rasulić
Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, 11000 Belgrade, Serbia
4 shared publications - Katarina Lalić
Clinic of Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Dr Subotića 13, 11000 Belgrade, Serbia
4 shared publications - Ljiljana Popović
Faculty of Medicine, University of Belgrade, Dr Subotića 8, 11000 Belgrade, Serbia
4 shared publications - Sandra Singh-Lukač
Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, 11000 Belgrade, Serbia
4 shared publications - Jelena Bogdanović
Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia
3 shared publications
Latest Publications
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinska istrazivanja
- No. 00,p. 39
Does correction of low-density lipoprotein cholesterol for lipoprotein(a) change the clinical classification of familial hypercholesterolemia? A retrospective study in patients referred to a lipid clinic
Introduction: Lipoprotein(a) [Lp(a)] contributes to measured low-density lipoprotein cholesterol (LDL-C), potentially affecting the classification of familial hypercholesterolemia (FH). This study evaluated how correcting LDL-C for the estimated cholesterol contribution of Lp(a) affects the clinical classification of FH using the Dutch Lipid Clinic Network (DLCN) criteria. Materials and Methods: This retrospective observational study included 339 patients evaluated for suspected FH at a tertiary lipid clinic. Corrected LDL-C was calculated by subtracting the estimated cholesterol content of Lp(a) (30% of Lp(a) mass) from pretreatment LDL-C. DLCN scores, recalculated from source data, and all four DLCN categories were determined before and after correction. Changes across categories were tested with the Bowker test of symmetry, and changes at the DLCN ≥6 and ≥3 thresholds with the McNemar test. Results: LDL-C correction reduced mean LDL-C from 5.02 ± 2.01 to 4.75 ± 2.01 mmol/L (p < 0.001). In total, 33 patients (9.7%; 95% CI 7.0-13.4%) moved to a lower DLCN category, and none moved upward (Bowker test, p < 0.001). The proportion with probable or definite FH (DLCN ≥6) decreased from 22.4% to 18.3%, and that with DLCN ≥3 from 54.3% to 49.0% (both p < 0.001). Conclusion: Correcting LDL-C for the estimated cholesterol contribution of Lp(a) modestly but significantly changed the clinical DLCN classification of patients with suspected FH, shifting approximately one in ten patients into a lower diagnostic category. Without a genetic reference standard, these findings reflect changes in clinical classification, not improved diagnostic accuracy.
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinska istrazivanja
- No. 00,p. 39
Does correction of low-density lipoprotein cholesterol for lipoprotein(a) change the clinical classification of familial hypercholesterolemia? A retrospective study in patients referred to a lipid clinic
Introduction: Lipoprotein(a) [Lp(a)] contributes to measured low-density lipoprotein cholesterol (LDL-C), potentially affecting the classification of familial hypercholesterolemia (FH). This study evaluated how correcting LDL-C for the estimated cholesterol contribution of Lp(a) affects the clinical classification of FH using the Dutch Lipid Clinic Network (DLCN) criteria. Materials and Methods: This retrospective observational study included 339 patients evaluated for suspected FH at a tertiary lipid clinic. Corrected LDL-C was calculated by subtracting the estimated cholesterol content of Lp(a) (30% of Lp(a) mass) from pretreatment LDL-C. DLCN scores, recalculated from source data, and all four DLCN categories were determined before and after correction. Changes across categories were tested with the Bowker test of symmetry, and changes at the DLCN ≥6 and ≥3 thresholds with the McNemar test. Results: LDL-C correction reduced mean LDL-C from 5.02 ± 2.01 to 4.75 ± 2.01 mmol/L (p < 0.001). In total, 33 patients (9.7%; 95% CI 7.0-13.4%) moved to a lower DLCN category, and none moved upward (Bowker test, p < 0.001). The proportion with probable or definite FH (DLCN ≥6) decreased from 22.4% to 18.3%, and that with DLCN ≥3 from 54.3% to 49.0% (both p < 0.001). Conclusion: Correcting LDL-C for the estimated cholesterol contribution of Lp(a) modestly but significantly changed the clinical DLCN classification of patients with suspected FH, shifting approximately one in ten patients into a lower diagnostic category. Without a genetic reference standard, these findings reflect changes in clinical classification, not improved diagnostic accuracy.
- Open Access
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinska istrazivanja
- No. 00,p. 29
Clinical significance and management of hypertriglyceridemia
Despite significant advances in lowering LDL cholesterol, a substantial residual risk for atherosclerotic cardiovascular disease (ASCVD) persists, largely driven by triglyceride-rich lipoproteins (TRLs). This narrative review emphasizes the importance of hypertriglyceridemia in the development of atherosclerotic cardiovascular disease and acute pancreatitis and clarifies the diagnostic dilemmas and current therapeutic options. This narrative review explores the pathophysiology, diagnostic criteria, and epidemiological impact of hypertriglyceridemia. TRLs, including chylomicrons and VLDL, contribute to atherosclerosis through the accumulation of cholesterol-rich "remnant particles" and apolipoprotein B (Apo B) in the subendothelial space. Recent epidemiological data, including findings from the Copenhagen General Population Study and the SIMETAP-HTG study, confirm that mild-to-moderate hypertriglyceridemia (1.7-5.6 mmol/L) is prevalent in approximately 25% of the population and is strongly associated with increased risks of myocardial infarction, heart failure, and multiorgan diseases such as diabetes and MASLD. Conversely, severe hypertriglyceridemia (≥10 mmol/L) significantly elevates the risk of acute pancreatitis. Current guidelines emphasize measuring fasting triglycerides, though non-fasting levels are increasingly recognized for screening. The paper concludes that secondary causes must be ruled out upon diagnosis and highlights non-HDL cholesterol as a critical secondary therapeutic target for comprehensive cardiovascular risk management. The final part of the review is focused on novel therapeutic options and emerging therapies for increased TRL.
- 1 January 2026
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinska istrazivanja
- No. 00,p. 29
Open AccessClinical significance and management of hypertriglyceridemia
Despite significant advances in lowering LDL cholesterol, a substantial residual risk for atherosclerotic cardiovascular disease (ASCVD) persists, largely driven by triglyceride-rich lipoproteins (TRLs). This narrative review emphasizes the importance of hypertriglyceridemia in the development of atherosclerotic cardiovascular disease and acute pancreatitis and clarifies the diagnostic dilemmas and current therapeutic options. This narrative review explores the pathophysiology, diagnostic criteria, and epidemiological impact of hypertriglyceridemia. TRLs, including chylomicrons and VLDL, contribute to atherosclerosis through the accumulation of cholesterol-rich "remnant particles" and apolipoprotein B (Apo B) in the subendothelial space. Recent epidemiological data, including findings from the Copenhagen General Population Study and the SIMETAP-HTG study, confirm that mild-to-moderate hypertriglyceridemia (1.7-5.6 mmol/L) is prevalent in approximately 25% of the population and is strongly associated with increased risks of myocardial infarction, heart failure, and multiorgan diseases such as diabetes and MASLD. Conversely, severe hypertriglyceridemia (≥10 mmol/L) significantly elevates the risk of acute pancreatitis. Current guidelines emphasize measuring fasting triglycerides, though non-fasting levels are increasingly recognized for screening. The paper concludes that secondary causes must be ruled out upon diagnosis and highlights non-HDL cholesterol as a critical secondary therapeutic target for comprehensive cardiovascular risk management. The final part of the review is focused on novel therapeutic options and emerging therapies for increased TRL.
- Open Access
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Journal of Medical Biochemistry
- Vol. 44 (9) , 2026-2034
Biochemical characterisation of familial hypercholesterolemia: Associations between genetic and lipid profiles
Background: Familial hypercholesterolemia (FH) is characterised by elevated low-density lipoprotein cholesterol (LDL-C) levels and an increased risk of premature cardiovascular disease. The present study aimed to investigate the genetic background, associated biochemical profiles, clinical manifestations, and therapeutic response in patients with clinically suspected FH in Serbia. Methods: A total of 101 patients with clinically suspected FH were recruited from the Clinic for Endocrinology, Diabetes and Metabolic Diseases in Serbia between 2015 and 2023. Clinical diagnosis was established using the Dutch Lipid Clinic Network (DLCN) criteria. Genetic profiles of all patients were previously determined using next-generation sequencing. Fasting serum lipids, apolipoprotein A-I [ApoA-I], apolipoprotein B [ApoB], and lipoprotein(a) (Lp(a)) were measured enzymatically. Levels of serum lipids were compared between genetically FH-positive (carriers of variants in LDLR, APOB, PCSK9 and LDLRAP1 genes) and FH-negative patients. Therapeutic response was assessed by achieving the LDL-C target level. Statistical analyses were conducted in SPSS (version 30.0). Results: Genetically confirmed FH patients exhibited significantly higher levels of ApoB (p=0.001) compared with variant-negative individuals, while ApoA-I (p=0.413) and Lp(a) (p=0.421) levels did not differ significantly between groups. Patients with pathogenic FH-associated variants were less likely to reach target LDL-C levels after therapy than those without identified variants. Conclusions: This study demonstrates biochemical diversity in familial hypercholesterolemia associated with genetic background in the Serbian population. Pathogenic FH mutations were associated with higher ApoB levels, underscoring the importance of combining genetic testing with lipid profiling for precise diagnosis and management.
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Journal of Medical Biochemistry
- Vol. 44 (9) , 2026-2034
Open AccessBiochemical characterisation of familial hypercholesterolemia: Associations between genetic and lipid profiles
Background: Familial hypercholesterolemia (FH) is characterised by elevated low-density lipoprotein cholesterol (LDL-C) levels and an increased risk of premature cardiovascular disease. The present study aimed to investigate the genetic background, associated biochemical profiles, clinical manifestations, and therapeutic response in patients with clinically suspected FH in Serbia. Methods: A total of 101 patients with clinically suspected FH were recruited from the Clinic for Endocrinology, Diabetes and Metabolic Diseases in Serbia between 2015 and 2023. Clinical diagnosis was established using the Dutch Lipid Clinic Network (DLCN) criteria. Genetic profiles of all patients were previously determined using next-generation sequencing. Fasting serum lipids, apolipoprotein A-I [ApoA-I], apolipoprotein B [ApoB], and lipoprotein(a) (Lp(a)) were measured enzymatically. Levels of serum lipids were compared between genetically FH-positive (carriers of variants in LDLR, APOB, PCSK9 and LDLRAP1 genes) and FH-negative patients. Therapeutic response was assessed by achieving the LDL-C target level. Statistical analyses were conducted in SPSS (version 30.0). Results: Genetically confirmed FH patients exhibited significantly higher levels of ApoB (p=0.001) compared with variant-negative individuals, while ApoA-I (p=0.413) and Lp(a) (p=0.421) levels did not differ significantly between groups. Patients with pathogenic FH-associated variants were less likely to reach target LDL-C levels after therapy than those without identified variants. Conclusions: This study demonstrates biochemical diversity in familial hypercholesterolemia associated with genetic background in the Serbian population. Pathogenic FH mutations were associated with higher ApoB levels, underscoring the importance of combining genetic testing with lipid profiling for precise diagnosis and management.
- Open Access
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinska istrazivanja
- Vol. 58 (3) , 197-206
Treatment of dyslipidemia: PCSK-9 in focus
Cardiovascular disease is the leading cause of death worldwide, accounting for one-third of the total global mortality. Dyslipidemia is one of the most common risk factors and plays a cardinal role in the development and progression of atherosclerotic cardiovascular disease. Since statin therapy is often insufficient, or cardiovascular disease continues to develop despite achieving target lipid levels, current attention is focused on new therapeutic options with significantly greater efficacy. The reduction in LDL cholesterol levels with PCSK-9 inhibitors is about 60% when used as monotherapy and as much as 85% when combined with high-intensity statins and/or other lipid-lowering therapies. Alirocumab and evolocumab are two monoclonal antibodies that effectively bind to the LDL receptor, interfering with its degradation. Inclisiran is a small interfering RNA that interferes with the synthesis of PCSK-9 molecules and effectively reduces LDL-C. Indications for PCSK-9 inhibitors usage are increasingly expanding due to the discovery of their pleiotropic effects. Additionally, the focus is on discovering new mechanisms of PCSK-9 inhibition that would open the door to the development of new therapeutic agents. Studies on the efficacy and safety of oral PCSK9 inhibitors are ongoing, along with early-stage clinical trials exploring gene-editing strategies for the treatment of dyslipidemias. The purpose of this review article is to provide an overview of the current knowledge on the application of PCSK-9 inhibitors.
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Medicinska istrazivanja
- Vol. 58 (3) , 197-206
Open AccessTreatment of dyslipidemia: PCSK-9 in focus
Cardiovascular disease is the leading cause of death worldwide, accounting for one-third of the total global mortality. Dyslipidemia is one of the most common risk factors and plays a cardinal role in the development and progression of atherosclerotic cardiovascular disease. Since statin therapy is often insufficient, or cardiovascular disease continues to develop despite achieving target lipid levels, current attention is focused on new therapeutic options with significantly greater efficacy. The reduction in LDL cholesterol levels with PCSK-9 inhibitors is about 60% when used as monotherapy and as much as 85% when combined with high-intensity statins and/or other lipid-lowering therapies. Alirocumab and evolocumab are two monoclonal antibodies that effectively bind to the LDL receptor, interfering with its degradation. Inclisiran is a small interfering RNA that interferes with the synthesis of PCSK-9 molecules and effectively reduces LDL-C. Indications for PCSK-9 inhibitors usage are increasingly expanding due to the discovery of their pleiotropic effects. Additionally, the focus is on discovering new mechanisms of PCSK-9 inhibition that would open the door to the development of new therapeutic agents. Studies on the efficacy and safety of oral PCSK9 inhibitors are ongoing, along with early-stage clinical trials exploring gene-editing strategies for the treatment of dyslipidemias. The purpose of this review article is to provide an overview of the current knowledge on the application of PCSK-9 inhibitors.